Illumina, Inc. (NASDAQ:ILMN)‘s stock had its “sell” rating reissued by analysts at Janney Montgomery Scott in a research note issued on Friday. They presently have a $125.00 price objective on the life sciences company’s stock. Janney Montgomery Scott’s price target would suggest a potential downside of 11.69% from the stock’s current price.
ILMN has been the subject of a number of other reports. CL King upgraded Illumina from a “neutral” rating to a “buy” rating in a research report on Friday. Citigroup Inc. lifted their price objective on Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Argus reiterated a “buy” rating and issued a $170.00 price objective (down from $205.00) on shares of Illumina in a research report on Friday, October 14th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $148.34 price objective for the company in a research report on Tuesday, January 3rd. Finally, Zacks Investment Research lowered Illumina from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 19th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $152.79.
Shares of Illumina (NASDAQ:ILMN) opened at 141.54 on Friday. The stock has a 50 day moving average of $130.13 and a 200-day moving average of $150.44. Illumina has a 52-week low of $119.37 and a 52-week high of $186.88. The stock has a market capitalization of $20.79 billion, a price-to-earnings ratio of 47.50 and a beta of 1.16.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.10. The firm earned $607 million during the quarter, compared to analyst estimates of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The company’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned $0.80 earnings per share. On average, equities research analysts predict that Illumina will post $3.32 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Stock Rating Reaffirmed by Janney Montgomery Scott” was published by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/illumina-inc-ilmn-stock-rating-reaffirmed-by-janney-montgomery-scott/340373.html.
In other news, EVP Omead Ostadan sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, December 8th. The stock was sold at an average price of $121.63, for a total transaction of $364,890.00. Following the sale, the executive vice president now owns 52,988 shares in the company, valued at approximately $6,444,930.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel Bradbury sold 600 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $136.34, for a total value of $81,804.00. Following the sale, the director now owns 17,065 shares in the company, valued at approximately $2,326,642.10. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Large investors have recently made changes to their positions in the company. Global X Management Co. LLC boosted its stake in shares of Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock worth $109,000 after buying an additional 560 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the period. Penserra Capital Management LLC boosted its stake in Illumina by 94.5% in the third quarter. Penserra Capital Management LLC now owns 708 shares of the life sciences company’s stock worth $128,000 after buying an additional 344 shares during the period. Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the period. Finally, B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund acquired a new stake in Illumina during the third quarter worth $171,000. Institutional investors own 92.94% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with our FREE daily email newsletter.